Academic health system working on AI dictation feature for Epic

An academic health system and a healthcare AI company are working on a new dictation feature that will be integrated directly into Epic.

According to an announcement, Rush University System for Health is collaborating with Suki, adopting the latter’s AI assistant across the health system. The tool is designed to improve administrative tasks across 28 specialties.

The move comes after a successful pilot, during which the Chicago-based health system saw a 10 percent increase in encounter volumes, resulting in increased patient access and a revenue boost. Rush said the AI also improved coding processes.

Rush said that 74% of its surveyed clinicians added that the AI assistant reduced their burnout levels. Some 95% expressed a desire to continue using it.

“On average it is saving me about 2 hours on charting, which is time I can now dedicate to answering inbox and sending results. It has also made my exam more efficient, improving the quality of care I provide to my patients,” Fiona Lynn, a nurse practitioner in neurology at Rush, said in a statement.

Rush will work with Suki on the development of a dictation feature for the Epic EHR, which will utilize voice-to-text technology. The tool aims to further reduce clerical burdens and time spent writing reports and taking notes necessary for patient care and claims filing.

The upcoming feature is currently in development. A timeline has not been established for the Epic rollout.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.